

Petra Reinke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7550036/publications.pdf>

Version: 2024-02-01

213
papers

12,068
citations

30070

54
h-index

32842

100
g-index

224
all docs

224
docs citations

224
times ranked

12714
citing authors

#	ARTICLE	IF	CITATIONS
1	Granulocyteâ€“Macrophage Colony-stimulating Factor to Reverse Sepsis-associated Immunosuppression. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 640-648.	5.6	540
2	Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncology, The, 2012, 13, 196-206.	10.7	349
3	Protection from cytomegalovirus after transplantation is correlated with immediate early 1â€“specific CD8 T cells. Journal of Experimental Medicine, 2005, 201, 1031-1036.	8.5	336
4	Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet, The, 2011, 377, 837-847.	13.7	326
5	Anti-Human Leukocyte Antigen and Donor-Specific Antibodies Detected by Luminex Posttransplant Serve as Biomarkers for Chronic Rejection of Renal Allografts. Transplantation, 2009, 87, 1505-1513.	1.0	313
6	Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines. Trends in Molecular Medicine, 2019, 25, 149-163.	6.7	288
7	High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nature Medicine, 2019, 25, 242-248.	30.7	280
8	T-cell epitope mapping by flow cytometry. Nature Medicine, 1998, 4, 975-978.	30.7	273
9	Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet, The, 2020, 395, 1627-1639.	13.7	266
10	Target Structures of the CD8⁺-T-Cell Response to Human Cytomegalovirus: the 72-Kilodalton Major Immediate-Early Protein Revisited. Journal of Virology, 1999, 73, 8179-8184.	3.4	262
11	Cytomegalovirus (CMV) Phosphoprotein 65 Makes a Large Contribution to Shaping the T Cell Repertoire in CMVâ€“Exposed Individuals. Journal of Infectious Diseases, 2002, 185, 1709-1716.	4.0	260
12	Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. European Journal of Immunology, 2000, 30, 1676-1682.	2.9	255
13	Terminally Differentiated CD8 ⁺ T Cells Negatively Affect Bone Regeneration in Humans. Science Translational Medicine, 2013, 5, 177ra36.	12.4	250
14	Treatment of solid organ transplant recipients with autologous Epstein Barr virusâ€“specific cytotoxic T lymphocytes (CTLs). Blood, 2006, 108, 2942-2949.	1.4	241
15	Effect of Anti-CD 20 Antibody Rituximab in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD). American Journal of Transplantation, 2005, 5, 2901-2906.	4.7	237
16	Monitoring Temporary Immunodepression by Flow Cytometric Measurement of Monocytic HLA-DR Expression: A Multicenter Standardized Study. Clinical Chemistry, 2005, 51, 2341-2347.	3.2	224
17	Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrology Dialysis Transplantation, 2009, 24, 1901-1908.	0.7	207
18	Antibodies to Î² adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. Brain, Behavior, and Immunity, 2016, 52, 32-39.	4.1	188

#	ARTICLE	IF	CITATIONS
19	CYTOMEGALOVIRUS INFECTION IN TRANSPLANT RECIPIENTS THE ROLE OF TUMOR NECROSIS FACTOR. Transplantation, 1994, 58, 675-680.	1.0	173
20	Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. Journal of Clinical Oncology, 2017, 35, 536-543.	1.6	168
21	Up-regulation of HIF in experimental acute renal failure: Evidence for a protective transcriptional response to hypoxia. Kidney International, 2005, 67, 531-542.	5.2	152
22	Short-term Hemodynamic Effects of Immunoabsorption in Dilated Cardiomyopathy. Circulation, 1997, 95, 1994-1997.	1.6	143
23	Distribution of human CMV-specific memory T cells among the CD8pos. subsets defined by CD57, CD27, and CD45 isoforms. European Journal of Immunology, 1999, 29, 2908-2915.	2.9	142
24	Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood, 2002, 100, 4059-4066.	1.4	141
25	Enzyme-Linked Immunosorbent Spot Assay for Donor-Reactive Interferon-Gamma-Producing Cells Identifies T-Cell Presensitization and Correlates with Graft Function at 6 and 12 Months in Renal-Transplant Recipients. Transplantation, 2004, 78, 1640-1646.	1.0	136
26	A Novel Link between Stress and Human Cytomegalovirus (HCMV) Infection: Sympathetic Hyperactivity Stimulates HCMV Activation. Virology, 2000, 272, 357-365.	2.4	132
27	MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy. Frontiers in Immunology, 2020, 11, 1091.	4.8	128
28	Regulatory T cell-mediated anti-inflammatory effects promote successful tissue repair in both indirect and direct manners. Frontiers in Pharmacology, 2015, 6, 184.	3.5	122
29	Circulating Alloreactive T Cells Correlate with Graft Function in Longstanding Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2008, 19, 1419-1429.	6.1	118
30	Overcoming Challenges Facing Advanced Therapies in the EU Market. Cell Stem Cell, 2016, 19, 293-297.	11.1	114
31	Old-for-Old Kidney Allocation Allows Successful Expansion of the Donor and Recipient Pool. American Journal of Transplantation, 2003, 3, 1434-1439.	4.7	111
32	Immunogenicity and Safety of Hepatitis A Vaccine in Liver and Renal Transplant Recipients. Journal of Infectious Diseases, 1999, 180, 2014-2017.	4.0	102
33	Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial. BMJ, The, 2020, 371, m3734.	6.0	101
34	BK polyomavirus infection and nephropathy: the virus-immune system interplay. Nature Reviews Nephrology, 2011, 7, 399-406.	9.6	100
35	ENHANCED GRANULYSIN mRNA EXPRESSION IN URINARY SEDIMENT IN EARLY AND DELAYED ACUTE RENAL ALLOGRAFT REJECTION. Transplantation, 2004, 77, 1866-1875.	1.0	97
36	RAPID DECLINE OF ANTIBODIES AFTER HEPATITIS A IMMUNIZATION IN LIVER AND RENAL TRANSPLANT RECIPIENTS. Transplantation, 2001, 71, 477-479.	1.0	95

#	ARTICLE	IF	CITATIONS
37	Renal Function, Efficacy, and Safety of Sirolimus and Mycophenolate Mofetil After Short-Term Calcineurin Inhibitor-Based Quadruple Therapy in De Novo Renal Transplant Patients: One-Year Analysis of a Randomized Multicenter Trial. <i>Transplantation</i> , 2010, 90, 175-183.	1.0	91
38	Relationship of Immunosuppression to Epstein-Barr Viral Load and Lymphoproliferative Disease in Pediatric Heart Transplant Patients. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 100-105.	0.6	88
39	Sustained BK Viruria as an Early Marker for the Development of BKV-Associated Nephropathy: Analysis of 4128 Urine and Serum Samples. <i>Transplantation</i> , 2009, 88, 89-95.	1.0	85
40	Immunoabsorption to remove α_2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. <i>PLoS ONE</i> , 2018, 13, e0193672.	2.5	83
41	Immunohistochemical Detection of Hypoxia-Inducible Factor-1 α in Human Renal Allograft Biopsies. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 343-351.	6.1	82
42	Deficient EBV-Specific B- and T-Cell Response in Patients with Chronic Fatigue Syndrome. <i>PLoS ONE</i> , 2014, 9, e85387.	2.5	82
43	High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. <i>Transplant Immunology</i> , 2009, 20, 238-242.	1.2	74
44	Serine proteinase inhibitor-9, an endogenous blocker of granzyme B/perforin lytic pathway, is hyperexpressed during acute rejection of renal allografts. <i>Transplantation</i> , 2003, 75, 1565-1570.	1.0	72
45	B-Cell-Related Biomarkers of Tolerance are Up-Regulated in Rejection-Free Kidney Transplant Recipients. <i>Transplantation</i> , 2013, 95, 148-154.	1.0	72
46	Salvage Chemotherapy for Refractory and Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) After Treatment With Single-Agent Rituximab. <i>Transplantation</i> , 2007, 83, 912-918.	1.0	70
47	QUANTITATIVE PCR ANALYSIS OF CYTOKINE TRANSCRIPTION PATTERNS IN PERIPHERAL MONONUCLEAR CELLS AFTER ANTI-CD3 REJECTION THERAPY USING TWO NOVEL MULTISPECIFIC COMPETITOR FRAGMENTS1. <i>Transplantation</i> , 1994, 58, 264-267.	1.0	69
48	Identification of Dialysis Patients with Panel-Reactive Memory T Cells before Kidney Transplantation Using an Allogeneic Cell Bank. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 573-580.	6.1	68
49	Absolute and functional iron deficiency in professional athletes during training and recovery. <i>International Journal of Cardiology</i> , 2012, 156, 186-191.	1.7	68
50	Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy. <i>Trends in Biotechnology</i> , 2020, 38, 1099-1112.	9.3	68
51	A NOVEL SELECTIVE EXTRACORPOREAL INTERVENTION IN SEPSIS. <i>Shock</i> , 2007, 28, 418-425.	2.1	66
52	Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation. <i>Kidney International</i> , 2013, 84, 1226-1236.	5.2	66
53	BKV, CMV, and EBV Interactions and their Effect on Graft Function One Year Post-Renal Transplantation: Results from a Large Multi-Centre Study. <i>EBioMedicine</i> , 2018, 34, 113-121.	6.1	66
54	Multi-Parameter Analysis of Biobanked Human Bone Marrow Stromal Cells Shows Little Influence for Donor Age and Mild Comorbidities on Phenotypic and Functional Properties. <i>Frontiers in Immunology</i> , 2019, 10, 2474.	4.8	64

#	ARTICLE	IF	CITATIONS
55	Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases. <i>Haematologica</i> , 2011, 96, 1067-1071.	3.5	61
56	Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs. <i>Cytotherapy</i> , 2013, 15, 362-383.	0.7	57
57	Sepsis: Time has come to focus on the later stages. <i>Medical Hypotheses</i> , 2008, 71, 203-208.	1.5	56
58	In vivo effect of bone marrow-derived mesenchymal stem cells in a rat kidney transplantation model with prolonged cold ischemia. <i>Transplant International</i> , 2011, 24, 1112-1123.	1.6	55
59	Immunogenicity of allogeneic mesenchymal stromal cells: what has been seen <i>in vitro</i> and <i>in vivo</i> ? <i>Regenerative Medicine</i> , 2015, 10, 305-315.	1.7	54
60	Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients. <i>Transplantation</i> , 2018, 102, 876-882.	1.0	53
61	Immunomodulatory placentalâ€œexpanded, mesenchymal stromal cells improve muscle function following hip arthroplasty. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 880-897.	7.3	53
62	BK-VP3 as a New Target of Cellular Immunity in BK Virus Infection. <i>Transplantation</i> , 2011, 91, 100-107.	1.0	51
63	CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor. <i>Transplantation</i> , 2017, 101, e315-e325.	1.0	49
64	Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1056-1066.	4.5	49
65	Epsteinâ€œBarr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. <i>Annals of Hematology</i> , 2006, 85, 478-484.	1.8	48
66	Evidence for Genetic Susceptibility Towards Development of Posttransplant Lymphoproliferative Disorder in Solid Organ Recipients. <i>Transplantation</i> , 2007, 84, 387-391.	1.0	46
67	Novel Approach for Improved Assessment of Phenotypic and Functional Characteristics of BKV-Specific T-Cell Immunity. <i>Transplantation</i> , 2011, 92, 1269-1277.	1.0	46
68	Modified ELISPOT technique â€” Highly significant inverse correlation of post-Tx donor-reactive IFN ³ -producing cell frequencies with 6 and 12â€œmonths graft function in kidney transplant recipients. <i>Transplant Immunology</i> , 2006, 16, 232-237.	1.2	44
69	Immunomodulation by adoptive regulatory Tâ€œcell transfer improves Coxsackievirus B3â€œinduced myocarditis. <i>FASEB Journal</i> , 2018, 32, 6066-6078.	0.5	42
70	Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibodyâ€œActivated Chimeric Antigen Receptorâ€œModified T Cells. <i>Journal of Immunology</i> , 2017, 199, 348-362.	0.8	41
71	Immunological monitoring of the inflammatory process: which variables? when to assess?. <i>The European Journal of Surgery</i> , 1999, 165, 70-72.	0.9	40
72	Human Cytomegalovirus Reactivation in Bone-Marrow-Derived Granulocyte/Monocyte Progenitor Cells and Mature Monocytes. <i>Intervirology</i> , 1999, 42, 308-313.	2.8	39

#	ARTICLE	IF	CITATIONS
73	The Influence of Recovery and Training Phases on Body Composition, Peripheral Vascular Function and Immune System of Professional Soccer Players. PLoS ONE, 2009, 4, e4910.	2.5	39
74	The genetic predisposition of natural killer cell to BK virus-associated nephropathy in renal transplant patients. Kidney International, 2013, 84, 359-365.	5.2	39
75	LATE ACUTE REJECTION IN LONG-TERM RENAL ALLOGRAFT RECIPIENTS. Transplantation, 1994, 58, 35-41.	1.0	39
76	Title is missing!. Molecular and Cellular Biochemistry, 2000, 212, 45-50.	3.1	37
77	DELAYED-TYPE HYPERSENSITIVITY-LIKE MECHANISMS DOMINATE LATE ACUTE REJECTION EPISODES IN RENAL ALLOGRAFT RECIPIENTS ^{1,2} . Transplantation, 1996, 61, 1233-1240.	1.0	37
78	Consider delayed immunosuppression into the concept of sepsis. Critical Care Medicine, 2008, 36, 3118.	0.9	36
79	Peripheral Blood-Derived Virus-Specific Memory Stem T Cells Mature to Functional Effector Memory Subsets with Self-Renewal Potency. Journal of Immunology, 2015, 194, 5559-5567.	0.8	36
80	VEGF -Supplemented extracellular matrix is sufficient to induce endothelial differentiation of human iPSC. Biomaterials, 2019, 216, 119283.	11.4	36
81	CYTOTOXIC EFFECTOR MOLECULE GENE EXPRESSION IN ACUTE RENAL ALLOGRAFT REJECTION. Transplantation, 2001, 72, 1158-1161.	1.0	36
82	Comparative characterization of decellularized renal scaffolds for tissue engineering. Biomedical Materials (Bristol), 2017, 12, 045005.	3.3	35
83	The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer. Science Translational Medicine, 2021, 13, .	12.4	35
84	Salvage Therapy for Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) With a Second Progression of PTLD After Upfront Chemotherapy: The Role of Single-Agent Rituximab. Transplantation, 2007, 84, 1708-1712.	1.0	34
85	Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock. Scandinavian Journal of Infectious Diseases, 2010, 42, 164-171.	1.5	34
86	HLA type-independent generation of antigen-specific T _H 1 cells for adoptive immunotherapy. European Journal of Immunology, 2005, 35, 2250-2258.	2.9	33
87	Predicting the outcome of renal transplantation. Journal of the American Medical Informatics Association: JAMIA, 2012, 19, 255-262.	4.4	33
88	Inflammatory activation and recovering BKV-specific immunity correlate with self-limited BKV replication after renal transplantation. Transplant International, 2014, 27, 290-301.	1.6	33
89	Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. Clinical Nephrology, 2015, 83 (2015), 11-21.	0.7	33
90	Adult Tissue Extracellular Matrix Determines Tissue Specification of Human iPSC-Derived Embryonic Stage Mesodermal Precursor Cells. Advanced Science, 2020, 7, 1901198.	11.2	33

#	ARTICLE	IF	CITATIONS
91	ASSOCIATION BETWEEN EPSTEIN-BARR VIRUS INFECTION AND LATE ACUTE TRANSPLANT REJECTION IN LONG-TERM TRANSPLANT PATIENTS ¹ . <i>Transplantation</i> , 2001, 72, 736-739.	1.0	33
92	Potent Early Immune Response After Kidney Transplantation in Patients of the European Senior Transplant Program. <i>Transplantation</i> , 2009, 87, 992-1000.	1.0	32
93	Human peripheral blood and bone marrow Epstein-Barr virus-specific T-cell repertoire in latent infection reveals distinct memory T-cell subsets. <i>European Journal of Immunology</i> , 2010, 40, 1566-1576.	2.9	32
94	Different risk factor profiles distinguish early-onset from late-onset BKV-replication. <i>Transplant International</i> , 2015, 28, 1081-1091.	1.6	32
95	Putting a price tag on novel autologous cellular therapies. <i>Cytotherapy</i> , 2016, 18, 1056-1061.	0.7	32
96	Bio-instructive hydrogel expands the paracrine potency of mesenchymal stem cells. <i>Biofabrication</i> , 2021, 13, 045002.	7.1	32
97	Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1060-1070.	0.7	31
98	Measurement of Anti-Human Cytomegalovirus T Cell Reactivity in Transplant Recipients and Its Potential Clinical Use: A Mini-Review. <i>Intervirolgy</i> , 1999, 42, 322-324.	2.8	30
99	IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment. <i>Transplant International</i> , 2011, 24, 892-903.	1.6	30
100	Burkitt post-transplantation lymphoma in adult solid organ transplant recipients. <i>Cancer</i> , 2012, 118, 4715-4724.	4.1	29
101	Treatment of Cytomegalovirus Disease with Valganciclovir in Renal Transplant Recipients: A Single Center Experience. <i>Transplantation</i> , 2004, 78, 283-285.	1.0	28
102	Molecular Phenotypes of Acute Rejection Predict Kidney Graft Prognosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 173-180.	6.1	28
103	The business case for cell and gene therapies. <i>Nature Biotechnology</i> , 2014, 32, 1192-1193.	17.5	28
104	Alterations of the immune response with increasing recipient age are associated with reduced long-term organ graft function of rat kidney allografts ¹ . <i>Transplantation</i> , 2003, 76, 1560-1568.	1.0	27
105	Monitoring tolerance and rejection in organ transplant recipients. <i>Biomarkers</i> , 2011, 16, S42-S50.	1.9	27
106	The Role of Pre-existing Cross-Reactive Central Memory CD4 T-Cells in Vaccination With Previously Unseen Influenza Strains. <i>Frontiers in Immunology</i> , 2019, 10, 593.	4.8	27
107	Mechanisms of Immune Tolerance in Liver Transplantation-Crosstalk Between Alloreactive T Cells and Liver Cells With Therapeutic Prospects. <i>Frontiers in Immunology</i> , 2019, 10, 2667.	4.8	27
108	CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients. <i>Molecular Therapy</i> , 2021, 29, 32-46.	8.2	27

#	ARTICLE	IF	CITATIONS
109	Preformed T cell alloimmunity and HLA eplet mismatch to guide immunosuppression minimization with tacrolimus monotherapy in kidney transplantation: Results of the CELLIMIN trial. <i>American Journal of Transplantation</i> , 2021, 21, 2833-2845.	4.7	27
110	Can We Use Biomarkers and Functional Assays to Implement Personalized Therapies in Transplantation?. <i>Transplantation</i> , 2009, 87, 1595-1601.	1.0	26
111	End-of-Treatment Positron Emission Tomography After Uniform First-Line Therapy of B-Cell Posttransplant Lymphoproliferative Disorder Identifies Patients at Low Risk of Relapse in the Prospective German PTLD Registry. <i>Transplantation</i> , 2018, 102, 868-875.	1.0	26
112	Super-Treg: Toward a New Era of Adoptive Treg Therapy Enabled by Genetic Modifications. <i>Frontiers in Immunology</i> , 2020, 11, 611638.	4.8	26
113	Pentoxifylline Promotes Replication of Human Cytomegalovirus In Vivo and In Vitro. <i>Blood</i> , 1997, 89, 3682-3690.	1.4	26
114	ABO desensitization affects cellular immunity and infection control after renal transplantation. <i>Transplant International</i> , 2015, 28, 1179-1194.	1.6	25
115	A revised strategy for monitoring BKV-specific cellular immunity in kidney transplant patients. <i>Kidney International</i> , 2015, 88, 1293-1303.	5.2	25
116	Rescue from lethal acute radiation syndrome (ARS) with severe weight loss by secretome of intramuscularly injected human placental stromal cells. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 1079-1092.	7.3	25
117	Colour-coded duplex sonography in the diagnostic assessment of vascular complications after kidney transplantation in children. <i>Pediatric Radiology</i> , 1997, 27, 898-902.	2.0	24
118	Interleukin-6 serum level assessment using a new qualitative point-of-care test in sepsis: A comparison with ELISA measurements. <i>Clinical Biochemistry</i> , 2008, 41, 893-898.	1.9	24
119	Diagnostic value of T-cell monitoring assays in kidney transplantation. <i>Current Opinion in Organ Transplantation</i> , 2009, 14, 426-431.	1.6	24
120	Pentoxifylline Promotes Replication of Human Cytomegalovirus In Vivo and In Vitro. <i>Blood</i> , 1997, 89, 3682-3690.	1.4	23
121	A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV. <i>Trends in Molecular Medicine</i> , 2014, 20, 632-642.	6.7	23
122	Prevalence and Clinical Correlates of Chronic Hepatitis E Infection in German Renal Transplant Recipients With Elevated Liver Enzymes. <i>Transplantation Direct</i> , 2018, 4, e341.	1.6	23
123	Generation of HCMV-specific T-cell Lines From Seropositive Solid-organ-transplant Recipients for Adoptive T-cell Therapy. <i>Journal of Immunotherapy</i> , 2009, 32, 932-940.	2.4	22
124	Preferential Expansion of Human Virus-Specific Multifunctional Central Memory T Cells by Partial Targeting of the IL-2 Receptor Signaling Pathway: The Key Role of CD4+ T Cells. <i>Journal of Immunology</i> , 2012, 188, 5189-5198.	0.8	22
125	Pretransplant prophylactic rituximab to prevent Epstein-Barr virus (<sc>EBV</sc>) viremia in <sc>EBV</sc>-seronegative kidney transplant recipients from <sc>EBV</sc>-seropositive donors: results of a pilot study. <i>Transplant Infectious Disease</i> , 2016, 18, 881-888.	1.7	22
126	Sepsis after renal transplantation: Clinical, immunological, and microbiological risk factors. <i>Transplant Infectious Disease</i> , 2017, 19, e12695.	1.7	22

#	ARTICLE	IF	CITATIONS
127	Study Design: Human Leukocyte Antigen Class I Molecule Aâ—02-Chimeric Antigen Receptor Regulatory T Cells in Renal Transplantation. <i>Kidney International Reports</i> , 2022, 7, 1258-1267.	0.8	22
128	Clonotype Analysis of Cytomegalovirus-Specific Cytotoxic T Lymphocytes. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 344-352.	6.1	21
129	Differential influenza H1N1-specific humoral and cellular response kinetics in kidney transplant patients. <i>Medical Microbiology and Immunology</i> , 2014, 203, 35-45.	4.8	21
130	Impaired thymic function and CD4+ T lymphopenia, but not mannose-binding lectin deficiency, are risk factors for <i>Pneumocystis jirovecii</i> pneumonia in kidney transplant recipients. <i>Transplant Immunology</i> , 2013, 28, 159-163.	1.2	20
131	ExÂvivo expanded natural regulatory T cells from patients with end-stage renal disease or kidney transplantation are useful for autologous cell therapy. <i>Kidney International</i> , 2018, 93, 1452-1464.	5.2	20
132	Heterologous Cytomegalovirus and Allo-Reactivity by Shared T Cell Receptor Repertoire in Kidney Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 2549.	4.8	20
133	Kidney transplant monitoring by urinary flow cytometry: Biomarker combination of T cells, renal tubular epithelial cells, and podocalyxin-positive cells detects rejection. <i>Scientific Reports</i> , 2020, 10, 796.	3.3	20
134	CD31+ Naive Th Cells Are Stable during Six Months Following Kidney Transplantation: Implications for Post-transplant Thymic Function. <i>American Journal of Transplantation</i> , 2005, 5, 1764-1771.	4.7	19
135	Accelerating Patientsâ€™ Access to Advanced Therapies in the EU. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 7, 15-19.	4.1	19
136	Evaluation of adherence and tolerability of prolongedâ€release tacrolimus (Advagrafâ„¸) in kidney transplant patients in Germany: A multicenter, noninterventional study. <i>Clinical Transplantation</i> , 2018, 32, e13142.	1.6	18
137	BKV Clearance Time Correlates With Exhaustion State and T-Cell Receptor Repertoire Shape of BKV-Specific T-Cells in Renal Transplant Patients. <i>Frontiers in Immunology</i> , 2019, 10, 767.	4.8	18
138	T Cell Response to the Cytomegalovirus Major Capsid Protein (UL86) Is Dominated by Helper Cells with a Large Polyfunctional Component and Diverse Epitope Recognition. <i>Journal of Infectious Diseases</i> , 2008, 197, 1455-1458.	4.0	17
139	Renal function to 5Âyears after late conversion of kidney transplant patients to everolimus: a randomized trial. <i>Journal of Nephrology</i> , 2015, 28, 115-123.	2.0	16
140	Adoptive transfer of exÂvivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD. <i>Molecular Therapy</i> , 2022, 30, 2298-2314.	8.2	16
141	HCMV-specific T-cell Therapy. <i>Journal of Immunotherapy</i> , 2013, 36, 93-101.	2.4	15
142	Unacceptable human leucocyte antigens for organ offers in the era of organ shortage: influence on waiting time before kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 880-889.	0.7	15
143	Intensive blood pressure control is associated with improved patient and graft survival after renal transplantation. <i>Scientific Reports</i> , 2019, 9, 10507.	3.3	15
144	Parallel generation of easily selectable multiple nephronal cell types from human pluripotent stem cells. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 179-192.	5.4	15

#	ARTICLE	IF	CITATIONS
145	Pretransplant immune risk assessment. <i>Current Opinion in Organ Transplantation</i> , 2009, 14, 650-655.	1.6	14
146	Simultaneous pancreas/kidney transplant recipients present with late-onset BK polyomavirus-associated nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1174-1182.	0.7	14
147	Virus-specific T-cell therapy in solid organ transplantation. <i>Transplant International</i> , 2016, 29, 515-526.	1.6	14
148	Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials. <i>BMC Nephrology</i> , 2018, 19, 237.	1.8	14
149	A novel approach reveals that HLA class 1 single antigen bead-signatures provide a means of high-accuracy pre-transplant risk assessment of acute cellular rejection in renal transplantation. <i>BMC Immunology</i> , 2019, 20, 11.	2.2	14
150	Two decades of the Eurotransplant Senior Program: the gender gap in mortality impacts patient survival after kidney transplantation. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 1091-1100.	2.9	14
151	Generation of EBV-specific T Cells for Adoptive Immunotherapy: A Novel Protocol Using Formalin-fixed Stimulator Cells to Increase Biosafety. <i>Journal of Immunotherapy</i> , 2007, 30, 817-824.	2.4	13
152	Lymphocyte markers and prediction of long-term renal allograft acceptance. <i>Current Opinion in Nephrology and Hypertension</i> , 2009, 18, 489-494.	2.0	13
153	State of the art on the research for biomarkers allowing individual, tailor-made minimization of immunosuppression. <i>Current Opinion in Organ Transplantation</i> , 2010, 15, 691-696.	1.6	13
154	T Cell PTLD Successfully Treated With Single-Agent Brentuximab Vedotin First-Line Therapy. <i>Transplantation</i> , 2016, 100, e8-e10.	1.0	13
155	Differential T cell response against BK virus regulatory and structural antigens: A viral dynamics modelling approach. <i>PLoS Computational Biology</i> , 2018, 14, e1005998.	3.2	13
156	Placenta-Derived Cell Therapy to Treat Patients With Respiratory Failure Due to Coronavirus Disease 2019. <i>2020</i> , 2, e0207.		13
157	Short-Term Anti-CD4 Plus Anti-TNF- α Receptor Treatment in Allogeneic Small Bowel Transplantation Results in Long-Term Survival. <i>Transplantation</i> , 2007, 84, 639-646.	1.0	12
158	Human Bone Marrow as a Source to Generate CMV-specific CD4+ T Cells With Multifunctional Capacity. <i>Journal of Immunotherapy</i> , 2009, 32, 907-913.	2.4	12
159	Transplantectomy is associated with presensitization with donor-reactive T cells and graft failure after kidney retransplantation: a cohort study. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 889-896.	0.7	12
160	The Identity Card of T Cells – Clinical Utility of T-cell Receptor Repertoire Analysis in Transplantation. <i>Transplantation</i> , 2019, 103, 1544-1555.	1.0	12
161	Advanced Therapy Medicinal Products' Translation in Europe: A Developers' Perspective. <i>Frontiers in Medicine</i> , 2022, 9, 757647.	2.6	12
162	Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy. <i>American Journal of Transplantation</i> , 2018, 18, 2965-2976.	4.7	11

#	ARTICLE	IF	CITATIONS
163	Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials. <i>Transplantation</i> , 2018, 102, 1914-1923.	1.0	11
164	Effects of Treatment of Asymptomatic Hyperuricemia on Graft Survival and Mortality in Kidney Transplant Recipients. <i>Annals of Transplantation</i> , 2016, 21, 350-359.	0.9	11
165	Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 25, 52-73.	4.1	11
166	Sequential Targeting of CD52 and TNF Allows Early Minimization Therapy in Kidney Transplantation: From a Biomarker to Targeting in a Proof-Of-Concept Trial. <i>PLoS ONE</i> , 2017, 12, e0169624.	2.5	10
167	Strong Expansion of Human Regulatory T Cells for Adoptive Cell Therapy Results in Epigenetic Changes Which May Impact Their Survival and Function. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 751590.	3.7	10
168	Freezing Medium Containing 5% DMSO Enhances the Cell Viability and Recovery Rate After Cryopreservation of Regulatory T Cell Products ex vivo and in vivo. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 750286.	3.7	10
169	Mannose-binding lectin deficiency is not associated with increased risk for polyomavirus nephropathy. <i>Transplant Immunology</i> , 2012, 26, 123-127.	1.2	9
170	Generation of a human induced pluripotent stem cell line from urinary cells of a healthy donor using an integration free vector. <i>Stem Cell Research</i> , 2016, 16, 314-317.	0.7	9
171	Comprehensive Characterization of a Next-Generation Antiviral T-Cell Product and Feasibility for Application in Immunosuppressed Transplant Patients. <i>Frontiers in Immunology</i> , 2019, 10, 1148.	4.8	9
172	Gene therapy: a possible future standard for HIV care. <i>Trends in Biotechnology</i> , 2015, 33, 374-376.	9.3	8
173	Increased alloreactivity and adverse outcomes in obese kidney transplant recipients are limited to those with diabetes mellitus. <i>Transplant Immunology</i> , 2017, 40, 8-16.	1.2	8
174	Diabetic kidney transplant recipients: Impaired infection control and increased alloreactivity. <i>Clinical Transplantation</i> , 2017, 31, e12986.	1.6	8
175	Kidney transplant recipients after nonrenal solid organ transplantation show low alloreactivity but an increased risk of infection. <i>Transplant International</i> , 2016, 29, 1296-1306.	1.6	7
176	Simultaneous pancreas/kidney transplant recipients are predisposed to tissue-invasive cytomegalovirus disease and concomitant infectious complications. <i>Transplant Infectious Disease</i> , 2017, 19, e12742.	1.7	7
177	RESTORE Survey on the Public Perception of Advanced Therapies and ATMPs in Europe – “Why the European Union Should Invest More!”. <i>Frontiers in Medicine</i> , 2021, 8, 739987.	2.6	7
178	FTY720 Prevents Anti-CD4 mAb-Induced Tolerance but Cannot Reverse Established Tolerance in a Rat Kidney Transplantation Model. <i>American Journal of Transplantation</i> , 2004, 4, 863-871.	4.7	6
179	To be, or not to be immunocompetent. <i>Critical Care</i> , 2013, 17, 185.	5.8	6
180	Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study. <i>Transplant International</i> , 2014, 27, 1192-1204.	1.6	6

#	ARTICLE	IF	CITATIONS
181	Effects of expanded allocation programmes and organ and recipient quality metrics on transplant-related costs in kidney transplantation – an institutional analysis. <i>Transplant International</i> , 2019, 32, 1074-1084.	1.6	6
182	Detection of pre-existing SARS-CoV-2-reactive T cells in unexposed renal transplant patients. <i>Journal of Nephrology</i> , 2021, 34, 1025-1037.	2.0	6
183	An Individual Patient's “Body-on Chips” How Organismoid Theory Can Translate Into Your Personal Precision Therapy Approach. <i>Frontiers in Medicine</i> , 2021, 8, 728866.	2.6	6
184	Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - A New Standard in Therapy?.. <i>Blood</i> , 2007, 110, 390-390.	1.4	6
185	Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - Moving Forward to a First Standard of Care: Results From a Prospective International Multicenter Trial.. <i>Blood</i> , 2009, 114, 100-100.	1.4	6
186	High-Mobility Group Box-1 Protein Serum Levels Do Not Reflect Monocytic Function in Patients with Sepsis-Induced Immunosuppression. <i>Mediators of Inflammation</i> , 2010, 2010, 1-6.	3.0	5
187	Risk-Stratified Cardiovascular Screening Including Angiographic and Procedural Outcomes of Percutaneous Coronary Interventions in Renal Transplant Candidates. <i>Journal of Transplantation</i> , 2014, 2014, 1-11.	0.5	5
188	Factors and outcomes in association with sepsis differ between simultaneous pancreas/kidney and single kidney transplant recipients. <i>Transplant Infectious Disease</i> , 2018, 20, e12848.	1.7	5
189	Generating Multiple Kidney Progenitors and Cell Types from Human Pluripotent Stem Cells. <i>Methods in Molecular Biology</i> , 2019, 1926, 103-115.	0.9	5
190	The TreaT-Assay: A Novel Urine-Derived Donor Kidney Cell-Based Assay for Prediction of Kidney Transplantation Outcome. <i>Scientific Reports</i> , 2019, 9, 19037.	3.3	5
191	Cytotoxic Effects of Rabbit Anti-thymocyte Globulin Preparations on Primary Human Thymic Epithelial Cells. <i>Transplantation</i> , 2019, 103, 2234-2244.	1.0	5
192	Preformed donor-reactive T cells that persist after ABO desensitization predict severe T cell-mediated rejection after living donor kidney transplantation – a retrospective study. <i>Transplant International</i> , 2020, 33, 288-297.	1.6	5
193	Editorial comment: variables affecting the presence of mesenchymal stromal cells in the peripheral blood and their relationship with apheresis product. <i>British Journal of Haematology</i> , 2020, 189, 593-596.	2.5	5
194	Risk factors for Epstein-Barr virus reactivation after renal transplantation: Results of a large, multi-centre study. <i>Transplant International</i> , 2021, 34, 1680-1688.	1.6	5
195	Vasodilation and Exercise Capacity in Patients with End-Stage Renal Disease: A Prospective Proof-of-Concept Study. <i>CardioRenal Medicine</i> , 2017, 7, 50-59.	1.9	4
196	Generation of a human induced pluripotent stem cell line from urinary cells of a healthy donor using integration free Sendai virus technology. <i>Stem Cell Research</i> , 2017, 21, 167-170.	0.7	4
197	The role of soluble mediators in the clinical course of EBV infection and B cell homeostasis after kidney transplantation. <i>Scientific Reports</i> , 2020, 10, 19594.	3.3	4
198	Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLT registry. <i>Annals of Hematology</i> , 2021, 100, 2043-2050.	1.8	4

#	ARTICLE	IF	CITATIONS
199	Cyclosporine A but Not Corticosteroids Support Efficacy of Ex Vivo Expanded, Adoptively Transferred Human Tregs in GvHD. <i>Frontiers in Immunology</i> , 2021, 12, 716629.	4.8	4
200	Culture surface influence on T-cell phenotype and function. <i>Clinical Hemorheology and Microcirculation</i> , 2013, 55, 501-512.	1.7	3
201	Fc γ -Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder. <i>Journal of Immunology Research</i> , 2014, 2014, 1-6.	2.2	3
202	Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study. <i>BMC Nephrology</i> , 2018, 19, 154.	1.8	3
203	The Value of a Rapid Test of Human Regulatory T Cell Function Needs to be Revised. <i>Frontiers in Immunology</i> , 2019, 10, 150.	4.8	3
204	Sex-Associated Differences in Cytomegalovirus Prevention: Prophylactic Strategy is Potentially Associated With a Strong Kidney Function Impairment in Female Renal Transplant Patients. <i>Frontiers in Pharmacology</i> , 2020, 11, 534681.	3.5	3
205	Intramuscular and intratendinous placenta-derived mesenchymal stromal-like cell treatment of a chronic quadriceps tendon rupture. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 434-442.	7.3	3
206	Late-acute renal allograft rejection and symptomless cytomegalovirus infection. <i>Lancet</i> , The, 1995, 345, 794.	13.7	2
207	Treatment of Anti-HLA Donor-Specific Antibodies Results in Increased Infectious Complications and Impairs Survival after Liver Transplantation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3986.	2.4	2
208	Generation of 20 human induced pluripotent stem cell lines from patients with focal segmental glomerulosclerosis (FSGS). <i>Stem Cell Research</i> , 2021, 54, 102406.	0.7	2
209	Early prediction of renal graft function: Analysis of a multi-center, multi-level data set. <i>Current Research in Translational Medicine</i> , 2022, 70, 103334.	1.8	2
210	Human iPSC-Derived Renal Cells Change Their Immunogenic Properties during Maturation: Implications for Regenerative Therapies. <i>Cells</i> , 2022, 11, 1328.	4.1	2
211	Cytomegalovirus infections in kidney transplant patients. <i>Transplantation Reviews</i> , 2002, 16, 121-130.	2.9	0
212	Dialysis therapy is associated with peripheral marginal zone B-cell augmentation. <i>Transplant Immunology</i> , 2020, 60, 101289.	1.2	0
213	Tacrolimus CYP3A Single-Nucleotide Polymorphisms and Preformed T- and B-Cell Alloimmune Memory Improve Current Pretransplant Rejection-Risk Stratification in Kidney Transplantation. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0